| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| PLUS THERAPEUTICS, INC. | Director | Common Stock | 0 | $0 | $0.49 | 18 Apr 2025 | Direct |
| ATOSSA THERAPEUTICS, INC. | CFO, Gen Counsel and Secretary | Stock Option (right to buy) | 558K | 02 Mar 2023 | Direct | ||
| PLUS THERAPEUTICS, INC. | Director | Stock Option (Right to Buy) | 40K | 13 Aug 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| PSTV | PLUS THERAPEUTICS, INC. | 13 Aug 2025 | 2 | $0 | 4 | Director | 15 Aug 2025, 16:29 |
| PSTV | PLUS THERAPEUTICS, INC. | 18 Apr 2025 | 0 | $0 | 3 | Director | 15 Aug 2025, 16:19 |
| ATOS | ATOSSA THERAPEUTICS, INC. | 02 Mar 2023 | 1 | $0 | 4 | CFO, Gen Counsel and Secretary | 06 Mar 2023, 15:10 |
| ATOS | ATOSSA THERAPEUTICS, INC. | 24 Feb 2022 | 1 | $0 | 4 | CFO, Gen Counsel and Secretary | 28 Feb 2022, 16:15 |
| ATOS | ATOSSA THERAPEUTICS, INC. | 14 May 2021 | 1 | $0 | 4 | CFO, Gen Counsel and Secretary | 18 May 2021, 16:18 |